Related Experiment Video
Updated: May 11, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Cardiovascular toxicity and sorafenib: a case report
Javier García-Lledó1, Lucía Cortejoso, María Tenorio Núñez
1Departments of 1Gastroenterology and Hepatology and 2Pharmacy, Hospital General Universitario Gregorio Marañón, Madrid, Spain; and 3Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain.
Sorafenib, a cancer drug, may increase the risk of aortic dilation, even with controlled blood pressure. This case study suggests a potential link between sorafenib and vascular adverse effects in patients with hepatocarcinoma.
Area of Science:
- Oncology
- Cardiology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is a major global health concern.
- Sorafenib is a targeted therapy used for advanced HCC.
- Cardiovascular side effects of sorafenib are documented, but aortic complications are less common.
Related Concept Videos
Drug Toxicity: Risk factors
Drug Toxicity: Overview
Drug toxicity: Drug–Drug Interaction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug toxicity: Idiosyncratic Reactions
